The Lyme Disease Network
Conference Abstract

Title:Use of Vancomycin in Chronic Persistent Lyme Disease
Authors:Burrascano JJ
Conference:9th Annual International Scientific Conference on Lyme Disease & Other Tick-Borne Disorders, Westin Copley Plaza Hotel, Boston, MA, April 19-20, 1996
Presenter:Joseph Burrascano, Jr., M.D.
Southampton Hospital

Because symptoms of Lyme disease that persist despite aggressive antibiotic therapy have been related to persistent infection, an expanded search for newer antibiotic regimens was undertaken.

Vancomycin has been shown to be effective in killing Borrelia burgdorferi in vitro, and a case report demonstrated the efficacy of this agent in a patient with ongoing symptoms unresponsive to other treatments. An expansion of that trial is now reported.

Twenty one patients with severe chronic Lyme disease unresponsive to more conventionally used oral and parenteral antibiotics were prescribed standard doses of vancomycin using a pulsed dosing schedule. Two patients had to drop out due to allergic reactions. Of the nineteen remaining patients, eighteen had a favorable response; in eleven the response was significantly greater than with any other agent previously used. In two such patients there was no apparent cure. None of these nineteen patients had any treatment related reactions, signs of nephro- or ototoxicity, or significant superinfections.

I conclude that vancomycin may be a safe and effective alternative for treating patients with severe, resistant Lyme disease when other agents have failed.

Unique ID: 96LDF026

The Lyme Disease Network of NJ, Inc.
43 Winton Road
East Brunswick, NJ 08816